文献速递肿瘤 PET/CT

前列腺癌患者注射后60与120分钟的18F-PSMA-1007 PET/CT:生物分布、肿瘤检出与activity动力学

18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-03-14

回顾性分析40例前列腺癌患者,在注射18F-PSMA-1007后60和120分钟行PET/CT,评估生物分布与病灶SUVmax变化。结果显示血池、膀胱和臀肌活性随时间显著下降(P < 0.001),肝、脾和肾摄取显著增加,骨髓稳定;病灶中位SUVmax从60分钟的10.98显著增至120分钟的15.51(P < 0.001),膀胱活性很低改善邻近病灶对比,但肝摄取增加可能限制肝转移检出敏感性。

要点

  • 前列腺癌病灶18F-PSMA-1007摄取在120分钟较60分钟显著增高(中位SUVmax 10.98至15.51,P < 0.001)。
  • 膀胱活性很低且随时间显著下降(P < 0.001),有助于改善邻近前列腺癌病灶的对比。
  • 肝脏摄取随时间显著增加,可能限制该示踪剂检测肝转移的敏感性。

核心结论

  • 前列腺癌病灶在注射后120分钟较60分钟显示18F-PSMA-1007摄取显著增加。
  • 膀胱中示踪剂蓄积很低,导致邻近前列腺癌病灶对比改善。
  • 肝脏中蓄积增加可能限制该示踪剂检测肝转移的敏感性。

研究设计与样本

  • 回顾性分析纳入40例连续转诊行PSMA PET/CT的前列腺癌患者,平均年龄68.7 ± 8.1岁。
  • 18F-PSMA-1007 PET/CT用于生化复发定位、原发分期或治疗随访。
  • 在注射后60和120分钟于肝、脾、肾、腹主动脉血池、骨髓(第4腰椎椎体)、膀胱和臀肌的代表性层面放置圆形感兴趣区。
  • 在恶性肿瘤病灶中于两个时间点在感兴趣体积内测量最大标准化摄取值(SUVmax)。
  • 比较注射后60分钟与120分钟的所有SUV值。

主要发现

  • 血池、膀胱和臀肌活性很低并随时间显著下降(P < 0.001)。
  • 肝、脾和肾摄取随时间显著增加(P < 0.001),骨髓摄取保持稳定。
  • 60分钟共检出135个前列腺癌病灶,120分钟检出136个病灶。
  • 病灶中位SUVmax从60分钟的10.98显著增至120分钟的15.51(P < 0.001)。

关键数值与推荐

  • 病灶中位SUVmax:60分钟10.98 vs 120分钟15.51(120分钟较60分钟升高,P < 0.001)。
  • 60分钟检出135个前列腺癌病灶 vs 120分钟检出136个病灶。
  • 血池、膀胱和臀肌活性随时间显著下降(P < 0.001);肝、脾和肾摄取随时间显著增加(P < 0.001);骨髓摄取保持稳定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: PSMA-targeted PET in patients with prostate cancer (PCa) has a significant impact on treatment decisions. By far the most frequently used PSMA ligand is 68Ga-labelled PSMA-11. However, due to the availability of larger amounts of activity, 18F-labelled PSMA ligands are of major interest. The aim of the present study was to evaluate the biodistribution and performance of the novel 18F-labelled ligand PSMA-1007 at two different time points. METHODS: This retrospective analysis included 40 consecutive patients (mean age 68.7 ± 8.1 years) referred for PSMA PET/CT. 18F-PSMA-1007 PET/CT was performed for localization of biochemical relapse, primary staging or therapy follow-up. Circular regions of interest were placed on representative slices of the liver, spleen, kidney, abdominal aortic blood pool, bone marrow (fourth lumbar vertebral body), urinary bladder and gluteus muscle at 60 and 120 min after injection. In malignant lesions the maximum standardized uptake (SUVmax) was measured within volumes of interest at both time points. All SUVs at 60 min were compared with those at 120 min after injection. RESULTS: The activity in the blood pool, urinary bladder and gluteus muscle was very low and decreased significantly over time (P < 0.001). Uptake in the liver, spleen and kidney showed a significant increase over time and uptake in the bone marrow remained stable. Overall, 135 PCa lesions were detected at 60 min and 136 lesions at 120 min after injection. The median SUVmax increased significantly (P < 0.001) from 10.98 to 15.51 between 60 and 120 min. CONCLUSION: PCa lesions show a significant increase in 18F-PSMA-1007 uptake at 120 min compared with 60 min after injection. In addition, accumulation of the tracer in the urinary bladder was very low leading to improved contrast of adjacent PCa lesions. Increasing accumulation in the liver may limit the sensitivity of the tracer in detecting liver metastases.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Rahbar K, Afshar-Oromieh A, Bögemann M, et al. 18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics. Eur J Nucl Med Mol Imaging. 2018. PMID: 29541812. doi:10.1007/s00259-018-3989-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。